目錄:愛必信(上海)生物科技有限公司>>抗體>>二抗>> abs8105753-Methyladenine
| 參考價 | 800 |
參考價:¥ 800
25mg
CAS:5142-23-4 純度:≥98% 分子量:149.15 分子式:C6H7N5 供貨周期:現(xiàn)貨 規(guī)格:25mg;50mg;200mg;500mg 貨號:abs810575 應用領域:化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 主要用途:Vps34;PI3Kγ
>| 25mg | 800元 | 999mg可售 |
更新時間:2025-10-30 14:15:53瀏覽次數(shù):1453評價
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!
| CAS | 5142-23-4 | 純度 | ≥98% |
|---|---|---|---|
| 分子量 | 149.15 | 分子式 | C6H7N5 |
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | 25mg;50mg;200mg;500mg |
| 貨號 | abs810575 | 應用領域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
| 主要用途 | Vps34;PI3Kγ |
3-Methyladenine
| 產(chǎn)品描述 | |
| 描述 | 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM. |
| 純度 | ≥98% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 3-甲基腺嘌呤; 3-MA;NSC 66389 |
| 外觀 | White to off white powder |
| 可溶性/溶解性 | Water :5 mg/mL (33.52 mM) DMSO :3 mg/mL warmed (20.11 mM) |
| 生物活性 | |
| 靶點 | Vps34;PI3Kγ |
| In vitro(體外研究) | The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5?/? MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2?/? cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. |
| In vivo(體內研究) | 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. |
| 研究領域 | |
| 研究領域 | ImmunologyInnate ImmunityTLR Signaling MetabolismPathways and ProcessesMetabolic signaling pathwaysLipid and lipoprotein metabolismLipid metabolism Signal TransductionSignaling PathwayLipid SignalingLipid Kinases Drug DiscoverySmall Molecule DrugLead Compound Discovery |